One study has demonstrated the suppressive capabilities of CB2R selective agonists on pDC production of IFN-α and TNF-α [21, 44], which are elevated in autoimmune conditions such as systemic lupus erythematosus and may also be implicated in DM pathogenesis [43, 45]. The gene discussed is TNF; the disease is systemic lupus erythematosus.